Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18742400 | 0.98 | KDM1A (0.56) | KDM1AKMT2AALDH1A1CYP3A4SLC6A4 | |
| SCHEMBL17982834 | 0.93 | KDM1A (0.54) | KDM1ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL521519 | 0.93 | KDM1A (0.54) | KDM1AKMT2ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5221231 | 0.91 | KDM1A (0.53) | KDM1A | |
| Hydrochloric Acid SCHEMBL18742809 | 0.91 | KDM1A (0.53) | KDM1ASLC6A4SLC6A2SLC6A3 | |
| SCHEMBL23647440 | 0.88 | KDM1A (0.50) | KDM1AKMT2AALDH1A1CYP3A4SLC6A4 | |
| SCHEMBL31158366 | 0.88 | KDM1A (0.50) | KDM1AKMT2AALDH1A1CYP3A4SLC6A4 | |
| SCHEMBL613824 | 0.87 | KDM1A (0.49) | KDM1AKMT2AALDH1A1CYP3A4SLC6A4 | |
| SCHEMBL6661373 | 0.85 | KDM1A (0.51) | KDM1AKMT2AALDH1A1SLC6A4OPRM1 | |
| Ethylene SCHEMBL11097079 | 0.84 | KDM1A (0.47) | KDM1AKMT2AALDH1A1SLC6A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-3490986-B1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-11-24 | — | — | EP | claimed |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-08-25 | — | — | US | claimed |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2019-06-06 | — | — | US | claimed |
| EP-3490986-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2019-06-05 | — | — | EP | claimed |
| WO-2018019929-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-02-01 | — | — | WO | claimed |
| US-20260116879-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4642764-A2 | AZAINDOLE ROCK INHIBITORS | Avicenna Biosciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12415805-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250250273-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-12286433-B1 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-12281115-B2 | Azaindole rock inhibitors | AVICENNA BIOSCIENCES, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250115605-A1 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| EP-1995241-B1 | Inhibitors of ion channels | ICAGEN INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415805-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885KMT2A 1053/4885ALDH1A1 3897/4885 |
| US-20250250273-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885KMT2A 1053/4885ALDH1A1 3897/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | KDM1A 1100/4885KMT2A 300/4885ALDH1A1 3102/4885 |
| US-12281115-B2 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885KMT2A 1053/4885ALDH1A1 3897/4885 |
| US-20260116879-A1 | AZAINDOLE ROCK INHIBITORS | PRKG2, PRKG1, ROCK2 | KDM1A 682/4885KMT2A 1024/4885ALDH1A1 3357/4885 |
| US-20090143358-A1 | INHIBITORS OF ION CHANNELS | TRPV1, TRPV5, TRPA1 | KDM1A 2129/4885KMT2A 1920/4885ALDH1A1 3113/4885 |
| US-20190169180-A1 | PIPERDINE CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, ACKR3 | KDM1A 1981/4885KMT2A 3120/4885ALDH1A1 428/4885 |
| US-20250115605-A1 | AZAINDOLE ROCK INHIBITORS | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885KMT2A 1053/4885ALDH1A1 3897/4885 |
| US-12286433-B1 | Azaindole rock inhibitors | ROCK2, ROCK1, ARHGDIA | KDM1A 492/4885KMT2A 1053/4885ALDH1A1 3897/4885 |
| US-10752620-B2 | Piperdine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | KDM1A 1981/4885KMT2A 3120/4885ALDH1A1 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.